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IMPORTANCE Although acute HIV infection contributes disproportionately to onward HIV
transmission, HIV testing has not routinely included screening for acute HIV infection.
OBJECTIVE To evaluate the performance of an HIV antigen/antibody (Ag/Ab) combination
assay to detect acute HIV infection compared with pooled HIV RNA testing.
DESIGN, SETTING, AND PARTICIPANTS Multisite, prospective, within-individual comparison
study conducted between September 2011 and October 2013 in 7 sexually transmitted
infection clinics and 5 community-based programs in New York, California,
and North Carolina. Participants were 12 years or older and seeking HIV testing,
without known HIV infection.
EXPOSURES All participants with a negative rapid HIV test result were screened for
acute HIV infection with an HIV Ag/Ab combination assay (index test) and pooled
human immunodeficiency virus 1 (HIV-1) RNA testing. HIV RNA testing was the reference
standard, with positive reference standard result defined as detectable HIV-1 RNA on an
individual RNA test.
MAIN OUTCOMES ANDMEASURES Number and proportionwith acute HIV infections
detected.
RESULTS Among 86836 participants with complete test results (median age, 29 years;
75.0%men; 51.8%menwho have sex with men), established HIV infection was diagnosed in
1158 participants (1.33%) and acute HIV infection was diagnosed in 168 participants (0.19%).
Acute HIV infection was detected in 134 participants with HIV Ag/Ab combination testing
(0.15% [95% CI, 0.13%-0.18%]; sensitivity, 79.8% [95% CI, 72.9%-85.6%]; specificity, 99.9%
[95% CI, 99.9%-99.9%]; positive predictive value, 59.0% [95% CI, 52.3%-65.5%]) and in 164
participants with pooled HIV RNA testing (0.19% [95% CI, 0.16%-0.22%]; sensitivity, 97.6%
[95% CI, 94.0%-99.4%]; specificity, 100% [95% CI, 100%-100%]; positive predictive value,
96.5% [95% CI, 92.5%-98.7%]; sensitivity comparison, P < .001). Overall HIV Ag/Ab
combination testing detected 82% of acute HIV infections detectable by pooled HIV RNA
testing. Compared with rapid HIV testing alone, HIV Ag/Ab combination testing increased the
relative HIV diagnostic yield (both established and acute HIV infections) by 10.4% (95% CI,
8.8%-12.2%) and pooled HIV RNA testing increased the relative HIV diagnostic yield by 12.4%
(95% CI, 10.7%-14.3%).
CONCLUSIONS AND RELEVANCE In a high-prevalence population, HIV screening using an HIV
Ag/Ab combination assay following a negative rapid test detected 82% of acute HIV
infections detectable by pooled HIV RNA testing, with a positive predictive value of 59%.
Further research is needed to evaluate this strategy in lower-prevalence populations and in
persons using preexposure prophylaxis for HIV prevention.
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A cute HIV infection contributes disproportionately toHIV transmission.1-4 A high viral load,5 which oftenpeaks at levels greater than 10000000 copies/mL,
and homogeneity of viral variants recently selected for
transmission3,6 both contribute to this highly infectious
phase. Individuals with acute HIV infection have de facto
engaged in high-risk behaviors and are often unaware that
they are infected with HIV. Identifying individuals with
acute HIV infection is critical to prevent further HIV
transmission,7 as diagnosis can lead to several effective HIV
prevention interventions. Acute HIV infection is character-
ized as the interval between the appearance of HIV RNA and
detection of HIV-specific antibodies.8 Acute HIV infection
can be diagnosed with assays that detect either HIV RNA
(the reference standard) or the p24 antigen (an HIV core
protein), which are both detectable early after HIV infection
and before an antibody response develops (eFigure in the
Supplement).8,9 Although HIV RNA testing using a pooled
protocol (in which multiple HIV antibody–negative speci-
mens are combined and tested together) can effectively
detect acute HIV infection, it has not been widely imple-
mented because only 1 RNA assay is US Food and Drug
Administration (FDA)–approved for HIV diagnosis, the pool-
ing protocol is logistically complex and time intensive, and
it may not be cost-effective.10 HIV immunoassays that
detect both the p24 antigen and anti-HIV antibody (fourth
generation antigen/antibody [Ag/Ab] combination immuno-
assays) are currently being implemented as the initial
screening test in the 2014 Centers for Disease Control and
Prevention (CDC) and Association of Public Health Labora-
tories (APHL)–recommended HIV diagnostic algorithm,8 can
be performed rapidly, and are likely cost-effective.11 How-
ever, HIV Ag/Ab combination assays have a lower sensitivity
compared with pooled HIV RNA testing, and its perfor-
mance at detecting acute HIV infection has not been estab-
lished. In a prospective study we evaluated the performance
of an HIV Ag/Ab combination assay to detect acute HIV
infection compared with pooled HIV RNA testing in a high-
prevalence population.
Methods
Study Design and Participants
This study was approved by local institutional review
boards, as indicated by local policies, for the University of
California at San Francisco, the University of North Carolina
at Chapel Hill, and the New York City Department of Health
and Mental Hygiene, and was approved by CDC through a
research determination in accordance with federal human
participants protection regulations and CDC policies and
procedures.13,14 Participants provided medical consent for
HIV testing (including screening for acute HIV infection),
and the study had a waiver of participant consent for
research based on an exempt status determined by local
institutional review boards. The Screening Targeted Popula-
tions to Interrupt On-going Chains of HIV Transmission
with Enhanced Partner Notification (STOP) study was a pro-
spective study examining implementation of HIV Ag/Ab
combination testing to detect acute HIV infection linked to
enhanced partner services in New York City, New York; San
Francisco, California; and Raleigh, Durham, and Winston-
Salem, North Carolina.12 Participants were 12 years or older
and receiving HIV testing at 1 of 12 facilities, including sexu-
ally transmitted infection clinics and community-based pro-
grams. Participants self-reported demographic (eg, age,
race, and ethnicity) and behavioral information based on
fixed categories. Race was included as a variable because
HIV disproportionately affects certain racial and ethnic
groups. Acute HIV testing was offered to consecutive sexu-
ally active men who have sex with men (MSM) at testing
venues in New York and California, and to all consecutive
patients (including MSM) receiving HIV testing at 3 sexually
transmitted infection clinics in North Carolina (Table 1).
TestMethods
Specimens from participants were initially screened with a
point-of-care rapid HIV test (OraQuick ADVANCE Rapid HIV-
1/2 Antibody Test, OraSure Technologies or Clearview HIV
1/2 STAT-PAK assay, Alere). Specimens with a negative test
result for the rapid test were tested for acute HIV infection
with the index test, a laboratory-based, fourth-generation
HIV Ag/Ab combination immunoassay (Abbott Architect
HIV Ag/Ab Combo Assay; Abbott Diagnostics) according to
the manufacturer’s specifications15 (eAppendix 1 in the
Supplement) and with pooled human immunodeficiency
virus 1 (HIV-1) RNA testing. The HIV Ag/Ab combination
immunoassay was considered reactive if the signal:cutoff
ratio result was 1.00 or more on the initial test and on at
least 1 of 2 additional repeat tests (ie, all reactive specimens
had 3 signal:cutoff ratio results).15
A combination of pooled and individual HIV-1 RNA test-
ing was used as the reference standard for acute HIV infec-
tion because HIV RNA is the first laboratory marker to
become detectable in the plasma after HIV infection (eFigure
in the Supplement).5,8,9 Because HIV RNA testing is expen-
sive and time intensive, multiple specimens that had tested
negative for HIV antibody (ie, do not have established HIV
infection) were combined into a pool and the HIV RNA assay
was performed on the pool.16 Although pooling increases the
lower limit of quantification (LLQ) of the assay by diluting
the contribution of each specimen, patients with acute HIV
infection often have markedly elevated HIV viral loads
(often exceeding 1 000000 copies/mL). In the pooled HIV
RNA testing protocol, if the pooled result was undetectable
for HIV RNA, all of the specimens in the pool had an unde-
tectable result. If the pooled test detected HIV RNA, each
specimen that contributed to the pool was tested individu-
ally to determine the HIV RNA detectable specimen. HIV-1
RNA testing was performed with either Aptima HIV-1 RNA
qualitative assay (Gen-Probe), a qualitative method with a
lower limit of detection of approximately 30 copies/mL,
or Abbott m2000 RealTime HIV-1 quantitative assay
(Abbott Diagnostics), a quantitative method with a LLQ of
40 copies/mL according to the manufacturer’s spec-
ifications.17 Pool size (ie, the number of specimens with a
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negative HIV rapid test result pooled together for an HIV
RNA test) ranged from 10 in California (LLQ = 400 copies/
mL), to 16 in New York (LLQ = 480 copies/mL), and to 80 in
North Carolina (LLQ = 2400 copies/mL).
The HIV Ag/Ab combination immunoassay and the
pooled HIV RNA testing were performed in parallel and a
final result was assigned for each assay without information
on the other assay’s result. If the HIV Ag/Ab combination
immunoassay and the pooled HIV RNA testing were discor-
dant, an additional individual HIV RNA test was performed.
In summary, if HIV Ag/Ab combination immunoassay was
nonreactive, the HIV-1 RNA reference standard was classi-
fied negative if the pooled HIV RNA result was undetect-
able. If either the HIV Ag/Ab combination immunoassay or
the pooled HIV RNA test result was positive, the HIV-1 RNA
reference standard result (positive or negative) was deter-
mined by the additional individual HIV RNA result (detect-
able or undetectable).
Reactive HIV Ag/Ab combination assay specimens were
also tested with 2 antibody-based confirmatory tests includ-
ing the Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad Laborato-
ries) and either an HIV-1 Western blot (Bio-Rad Laboratories)
or an HIV-1 immunofluorescent assay (Sanochemia) per
package insert.18 The Multispot was included in this analy-
sis because it is now the recommended confirmatory test for
HIV diagnosis in the 2014 CDC/APHL HIV laboratory testing
recommendations8 (eAppendix 1 in the Supplement).
Acute HIV infection was defined by a negative result for
the rapid HIV test followed by a reactive result for the HIV
Ag/Ab combination assay, or detectable HIV RNA on pooled
HIV RNA testing confirmed with an individual HIV RNA
test. Established HIV infection was defined as HIV infection
detected by a rapid HIV test and confirmed by a reactive
Multispot or positive HIV-1 Western blot result, with discor-
dant confirmatory results resolved with HIV-1 RNA testing.
Because the majority of testing occurred among MSM at 2 of
Table 1. Characteristics and Risk Behavior Information Stratified by Sitea
Variable
No. (%)
New York
(n = 20 884)
California
(n = 29 335)
North Carolina
(n = 36 617)
Total
(N = 86 836)b
Age, y
<25 4716 (22.6) 3520 (12.0) 15 400 (42.1) 23 636 (27.2)
25 to 34 10 691 (51.2) 12 144 (41.4) 11 378 (31.1) 34 213 (39.4)
35 to 44 3495 (16.7) 7221 (24.6) 5109 (14.0) 15 825 (18.2)
≥45 1982 (9.5) 6405 (21.8) 3649 (10.0) 12 036 (13.9)
Missing 0 45 (0.2) 1081 (2.6) 1126 (1.3)
Median (IQR) 29 (25-35) 33 (27-43) 26 (22-34) 29 (24-38)
Gender
Male 19 670 (94.2) 28 541 (97.3) 16 875 (46.1) 65 086 (75.0)
Female 1141 (5.5) 641 (2.2) 18 708 (51.1) 20 490 (23.6)
Transgender or other 73 (0.4) 123 (0.5) 6 (0.02) 202 (0.2)
Missing 0 30 (0.1) 1028 (2.8) 1058 (1.2)
Race/ethnicity
Black/African American 4005 (19.2) 1404 (4.8) 25 572 (69.8) 30 981 (35.7)
Hispanic/Latino 4518 (21.6) 5475 (18.7) 4147 (11.3) 14 140 (16.3)
White 9703 (46.5) 16 929 (57.7) 4801 (13.1) 31 433 (36.2)
Asian 1425 (6.8) 3486 (11.9) 134 (0.4) 5045 (5.8)
Other 22 (0.1) 616 (2.1) 63 (0.2) 701 (0.8)
Unknown 1211 (5.8) 1425 (4.9) 1900 (5.2) 4536 (5.2)
Risk Behaviors in Previous 12 Monthsc
Male participants only (n = 65 086)
Sex with men 17 910 (91.1) 25 355 (88.8) 1690 (10.0) 44 955 (69.1)
Sex with women only 0 1136 (4.0) 11 978 (71.0) 13 114 (20.2)
Female participants only (n = 20 490)
Sex with MSM 147 (12.9) 103 (16.1) 60 (0.3) 310 (1.5)
Sex with men (but not MSM) 0 460 (71.8) 14 942 (79.9) 15 402 (75.2)
Sex with women only 0 22 (3.4) 367 (2.0) 389 (1.9)
All participants (n = 86 836)
Sex with an HIV-infected sex partner 1145 (5.5) 6758 (23.0) 337 (0.9) 8240 (9.5)
Sex in exchange for money or drugs 0 17 (0.1) 234 (0.6) 251 (0.3)
Injection drug use 134 (0.6) 519 (1.8) 88 (0.2) 741 (0.9)
Abbreviations: IQR, interquartile
range; MSM, menwho have sex
with men.
a Characteristics and risk behavior
information are self-reported at the
time of testing. The test result (and
information collected at that test
event) is the unit of analysis.
Participants could be diagnosed
with HIV infection (either acute or
established) only once in this study,
but participants with a negative HIV
test result could be tested again.
b Thirty-one participants without
complete HIV testing (missing a
combination Ag/Ab combination
assay or pooled HIV RNA result)
were excluded.
c Each risk behavior (eg, sex with
men) was self-reported as “yes” by
checking a box and “no” by not
checking a box. Therefore, among
all male participants, 44 955men
(69.1%) indicated that they have sex
with men and the remaining 20 131
men (30.9%) did not indicate that
they have sex with men.
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the sites, an analysis of risk for acute HIV infection was con-
ducted among MSM only.
Statistical Analysis
The primary analysis was a within-individual comparison of
HIV Ag/Ab combination and pooled HIV RNA test results.
The unit of analysis was a test; although an individual could
contribute only 1 positive result (subsequent tests were
excluded after an HIV diagnosis), individuals with negative
test results were encouraged to return every 3 months for
testing. The frequencies of acute HIV infection detected
with these 2 assays were described and compared. The
McNemar test was used to test for differences in propor-
tions (categorical variables). Indeterminate HIV Ag/Ab
combination or pooled HIV RNA test results were repeated
and participants missing either test were excluded from
the analysis. The Wilcoxon rank sum test (continuous
variables), the χ2 and Fisher exact tests (2-level categorical
variables), and a log-linked binomial regression model
(Proc Genmod; >2-level categorical variables19) were used to
evaluate for associations between acute HIV infection and
demographic and behavioral information.20 Missing demo-
graphic data (eg, race) was categorized into a “missing” cat-
egory if not present on the data collection form or if the par-
ticipant refused to provide an answer, and this “missing”
category was included in the analysis. Statistical signifi-
cance was indicated by a 2-sided P value less than .05. All
analyses, including calculations of sensitivity, specificity,
and positive predictive value and their respective 95% con-
fidence intervals by exact (Clopper-Pearson) methods, were
performed using SAS (SAS Institute), version 9.3. The
intended sample size for this study was 109 acute HIV infec-
tions, which would provide adequate power (β = .1 and
α = .05) to detect a 13% difference in the proportion of acute
HIV infections detected by the HIV Ag/Ab combination
assay compared with pooled HIV RNA testing.
Results
Between September 2011 and October 2013, 86 867 HIV
tests were performed (Figure 1). Among 86 836 with com-
plete HIV testing results, the median age was 29 years (in-
terquartile range [IQR], 24-38), the majority (75.0%) of
those testing were men (Table 1), and 51.8% were MSM.
Among male participants (n = 65086), 69.1% reported hav-
ing sex with men. The majority of female participants
(n = 18 708 of 20 490; 91.3%) and male participants who
reported having sex with women only (n = 11 978 of 13 114;
91.3%) were tested in North Carolina (Table 1).
Established HIV infection (rapid HIV test reactive and
confirmed) was diagnosed in 1158 individuals (1.33%),
with few rapid HIV test results (n = 19; 0.02% of all tests,
1.6% of all positive tests) determined to be false-positive
(Figure 2). The HIV Ag/Ab combination assay result was
repeatedly reactive for all 1158 with established HIV infec-
tion and negative for all 19 rapid specimens with a false-
positive result. Western blot and immunofluorescent assay
test results were positive in 1143 of the 1158 specimens
(98.7%) determined to have established HIV infection but
were indeterminate (n = 9; 0.8%) or negative (n = 6; 0.5%)
in 15 established HIV infection specimens (Figure 2). Mul-
tispot confirmatory testing was HIV-1 reactive in 1140 of the
1158 specimens (98.4%) determined to have established HIV
infection but was indeterminate (n = 10; 0.9%) or negative
(n = 4; 0.3%) in 14 established HIV infection specimens
(Figure 2).
Acute HIV infection was diagnosed in 168 individuals
(0.19%) by testing specimens that were negative by rapid
HIV testing (n = 85 690) with HIV Ag/Ab combination
and pooled HIV RNA assays (eTable 1 in the Supplement).
The Ag/Ab combination assay was reactive in 227 of these
specimens, of which 134 (0.15% [95% CI, 0.13%- 0.18%])
were confirmed as acute HIV infection on individual HIV
RNA testing, and 93 (0.11% [95% CI, 0.09%-0.13%]) were
determined to be false-positive test results (Figure 1). The
positive predictive value for acute HIV infection of a reac-
tive Ag/Ab combination assay result after a negative rapid
HIV test was 59.0% (95% CI, 52.3%-65.5%). Pooled HIV-1
RNA testing was reactive in 170 of 85 690 rapid negative
specimens (0.20%), of which 164 (0.19%) were determined
to be acute HIV infection on individual HIV-1 RNA testing.
Four results from pooled HIV-1 RNA testing (0.005% of
the rapid negative specimens [95% CI, 0.00%– 0.02%])
were determined to be false-negative, and 6 results
(0.007% [95% CI, 0.00%-0.02%]) were determined to be
false-positive.
Of 168 acute HIV infections diagnosed in this study, HIV
Ag/Ab combination testing detected 134 acute infections
(acute HIV infection: sensitivity, 79.8% [95 CI, 72.9%-
85.6%]; specificity, 99.9% [95% CI, 99.9%-99.9%]; positive
predictive value, 59.0% [95% CI, 52.3%-65.5%]). Pooled HIV
RNA testing detected 164 acute infections (sensitivity,
97.6% [95% CI, 94.0%-99.4%]; specificity, 100% [95% CI,
100%-100%]; positive predictive value, 96.5% [95% CI,
92.5%-98.7%]) (sensitivity comparison, P < .001). Overall,
HIV Ag/Ab combination testing detected 82% of acute HIV
infections detectable by pooled HIV RNA testing. Acute
infections detectable by pooled HIV RNA testing only
(n = 34) had a lower median HIV-1 viral load (6019
copies/mL [IQR, 1225-25 866]) than those reactive on HIV
Ag/Ab combination testing (750 000 copies/mL [IQR,
224 152-2033422]; P < .001). The full testing results of the 4
acute infections (2.4%) that were reactive on the Ag/Ab
combination testing but negative on pooled HIV RNA test-
ing are available online (eTable 2 in the Supplement). All
acute infections detected by HIV Ag/Ab combination testing
were also tested with the Multispot antibody assay (eAppen-
dix 2 in the Supplement).
Based on the number of established HIV infections diag-
nosed with rapid HIV testing alone (n = 1158; 1.33%), the
addition of Ag/Ab combination testing increased the abso-
lute diagnostic yield by 0.15% (95% CI, 0.13%-0.18%) and
the relative diagnostic yield by 10.4% (95% CI, 8.8%-12.2%)
(Table 2). Pooled RNA testing increased the absolute and
relative diagnostic yields by 0.19% (95% CI, 0.16%-0.22%)
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and 12.4% (95% CI, 10.7%-14.3%), respectively, compared
with rapid HIV testing (Table 2), and by 0.04% (95% CI,
0.03%-0.05%) and 2.6% (95% CI, 1.8%-3.6%), respectively,
compared with HIV Ag/Ab combination testing. This
increase in absolute diagnostic yield from Ag/Ab combina-
tion testing ranged from an increase of 0.04% in North
Carolina and 0.15% in New York, to 0.21% in California. The
increase in relative diagnostic yield from Ag/Ab combina-
tion testing ranged from 7.6% in North Carolina and 8.5% in
New York, to 14.7% in California (Table 2).
Because HIV testing focused on sexually active MSM in
both New York City, New York, and San Francisco, California
(86% of all tests), a subanalysis of MSM was conducted to
evaluate risk factors for acute HIV infection (Table 3).
Among 44955 MSM tested at all 3 sites, 1107 (2.46%) were
diagnosed with HIV infection, including 956 (2.13%) with
established HIV infection and 151 (0.34%) with acute HIV
infection. Among only MSM, the addition of Ag/Ab combi-
nation testing to rapid HIV testing alone increased the rela-
tive diagnostic yield by 11.2% (95% CI, 9.4% to 13.3%), and
pooled HIV RNA testing increased the relative diagnostic
yield by 13.4% (95% CI, 11.5% to 15.6%). Younger (<25 years
of age) MSM had a higher frequency of acute HIV infection
compared with older (≥45 years) MSM, but the difference
was not statistically significant (0.40% for younger MSM vs
0.28% for older MSM; risk difference [RD], 0.12% [95% CI,
−0.06% to 0.31%]; P = .19). Compared with white MSM,
there were higher frequencies of acute HIV infection among
African American or black MSM (0.54% for African Ameri-
can or black MSM vs 0.28% for white MSM; RD, 0.26% [95%
CI, 0.05% to 0.48%]; P = .01) and Hispanic or Latino MSM
(0.43% for Hispanic or Latino MSM vs 0.28% for white
MSM; RD, 0.16% [95% CI, 0.01% to 0.31%]; P = .04). Overall,
only 16.9% (n = 7603) of MSM reported having an
HIV-infected sex partner at the time of testing, but these
MSM had a higher frequency of acute HIV infection than
MSMwho did not report an HIV-infected sex partner (0.47%
for MSM with HIV-infected sex partner vs 0.31% for MSM
without HIV-infected sex partner; RD, 0.16% [95% CI,
0.00% to 0.33%]; P = .048).
Figure 1. Flow of Specimens Screened for Acute HIV InfectionWith an HIV Ag/Ab Combination Assay (Index Test) and HIV-1 RNA Testing
(Reference Standard Test)
7 Excluded
3 Had a previously diagnosed HIV infection
3 Involved in an HIV vaccine trial
1 Lab error
86 874 Potentially eligible participants
86 867 Eligible participants with a rapid
HIV test result
85 690 Negative rapid HIV test result
227 Index test reactive 85 461 Index test nonreactive 2 Index test invalid
Reference standard testing
227 Had individual HIV-1 RNA testing
Reference standard testing
1 Had individual HIV-1 RNA testing
Reference standard testing
85 432 Had pooled and individual
HIV-1 RNA testing a
Index test
HIV Ag/Ab combination assay testing
for acute HIV infection
Final diagnosis
134 Acute HIV infection b
93 HIV negative result
Final diagnosis
34 Acute HIV infection b
85 398 HIV negative result
Final diagnosis
0 Acute HIV infection
1 HIV negative result
29 Had no HIV-1 RNA
reference standard
testing (lab error)
1 Had no HIV-1 RNA
reference standard
testing (lab error)
1177 Preliminary positive rapid HIV
test result
1177 Not tested for acute HIV
infection (see Figure 2)
Ag indicates antigen; Ab, antibody; HIV-1, human immunodeficiency virus 1.
Brown boxes indicate specimens with complete HIV test results and included in
the primary analysis.
a An additional individual HIV-1 RNA assay was performed if the pooled HIV-1
RNA testing had a positive result.
bAcute HIV infection was diagnosed with (1) a reactive HIV Ag/Ab combination
assay or detectable HIV RNA on pooled HIV RNA testing and (2) detectable
HIV RNA on an individual HIV RNA test.
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Discussion
In this prospective study evaluating HIV testing in a high–HIV
prevalence population, the HIV Ag/Ab combination assay in
place of rapid HIV testing increased the absolute HIV diag-
nostic yield by 0.15% (a 10.4% increase in the relative diag-
nostic yield) and diagnosed 82% of the acute HIV infections
detectable by pooled RNA testing. Because rapid HIV testing
detected HIV infection in only 87.3% of HIV-infected partici-
pants, alternative strategies such as using a laboratory-based
HIV Ag/Ab combination assay that can detect acute infection
should be considered in high-prevalence populations in the
United States.
These data are novel in several respects. First, this study
detected more acute HIV infections (n = 168) than have
been previously diagnosed in a study in the United States to
our knowledge. Diagnosing acute HIV infection has been
considered a rare event; preliminary data from the US
National HIV Surveillance System on a subset of new HIV
diagnoses indicated that only 3.1% of HIV infections were
diagnosed in the acute phase from 2008 through 2012.21 In
our study, almost 12% of HIV infections were detected in the
acute phase, demonstrating that acute infection can be
diagnosed if the testing strategy has adequate acute HIV
infection sensitivity. Second, to our knowledge, this is the
only US prospective study to evaluate the performance of
the HIV Ag/Ab combination assay compared with the refer-
ent standard, HIV RNA testing. Previous studies have evalu-
ated the relative performance of these tests in vitro with ret-
rospective testing of stored specimens22,23 or have been
performed in Asia, where the proportion of HIV diagnoses
in the acute phase of infection was low (1.4%), and pooled
HIV RNA testing was only performed in participants with a
negative HIV Ag/Ab combination assay result.24 Third, this
study prospectively compared the performance of the HIV
Ag/Ab combination test and HIV RNA testing following
rapid point-of-care testing. In 2013, 58.5% of all CDC-
funded HIV tests performed in persons at high risk for HIV
infection were rapid HIV antibody tests25 and in our study
greater than 12% of HIV diagnoses were not detected with
rapid HIV testing alone.
Pooled HIV-1 RNA testing detected almost all of the
acute infections in this study, consistent with data from
seroconversion studies demonstrating that HIV RNA can be
detected approximately 6 days before the earliest detection
of p24 antigen.22 However, few HIV testing sites have access
to a laboratory with the logistic capacity to perform timely
pooled testing at a sustainable cost; including labor costs,
HIV-1 RNA testing costs approximate $160.07 per test com-
pared with $4.23 per test for Ag/Ab combination testing.11 In
Figure 2. Flow of Additional HIV Testing on SpecimensWith a Reactive
Rapid HIV Test Result
1177 Participants had a preliminary
positive rapid HIV test result
HIV Ag/Ab combination assay testing
Established HIV infection
1143 Positive
9 Indeterminate a
6 Negative a
0 Not tested
Western blot or HIV-1
immunofluorescent assay result
1140 HIV-1 reactive
10 HIV-1 indeterminate a
1 HIV-1 and HIV-2 reactive a
4 Negative a
3 Not tested a
Multispot result
1158 Reactive 19 Nonreactive
False-positive rapid HIV test
0 Positive
2 Indeterminate b
15 Negative
2 Not tested b
Western blot or HIV-1
immunofluorescent assay result
1 HIV-1 reactive b
0 HIV-1 indeterminate
0 HIV-1 and HIV-2 reactive
14 Negative
4 Not tested b
Multispot result
Ag indicates antigen; Ab, antibody.
a These specimens were reactive on HIV-1 RNA testing confirming HIV infection.
b These specimens had a negative result with additional testing.
Table 2. Diagnostic YieldWith the Addition of Assays That Detect Acute HIV Infection
Testing Following a Rapid HIV Test
HIV Tests,
No.
HIV Infections
Detected With
Rapid HIV Test,
No. (%)
Additional HIV Infections
Diagnosed (Absolute
Increased Diagnostic
Yield), No. (%) [95% CI]
Relative Diagnostic
Yield Following a
Rapid HIV Testing, %
(95% CI)a
HIV Ag/Ab Combination Testing
Overall 86 836 1158 (1.33) 134 (0.15) [0.13-0.18] 10.4 (8.8-12.2)
MSM only 44 955 956 (2.13) 121 (0.27) [0.22-0.32] 11.2 (9.4-13.3)
New York 36 617 603 (1.65) 56 (0.15) [0.12-0.20] 8.5 (6.4-10.9)
California 29 335 360 (1.23) 62 (0.21) [0.16-0.27] 14.7 (11.5-18.4)
North Carolina 36 617 195 (0.53) 16 (0.04) [0.02-0.07] 7.6 (4.4-12.0)
Pooled HIV RNA Testing
Overall 86 836 1158 (1.33) 164 (0.19) [0.16-0.22] 12.4 (10.7-14.3)
MSM only 44 955 956 (2.13) 148 (0.33) [0.28-0.39] 13.4 (11.5-15.6)
New York 36 617 603 (1.65) 69 (0.19) [0.15-0.24] 10.3 (8.1-12.8)
California 29 335 360 (1.23) 77 (0.26) [0.21-0.33] 17.6 (14.2-21.5)
North Carolina 36 617 195 (0.53) 18 (0.05) [0.03-0.08] 8.5 (5.1-13.0)
Abbreviations: Ab, antibody; Ag,
antigen; MSM, menwho have sex
with men.
a The relative diagnostic yield was
calculated as the number of
additional acute HIV infections
diagnosed divided by the total
number of HIV infections (sum of
HIV infections detected with the
rapid HIV test and additional acute
HIV infection diagnosed).
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addition, health insurance can be billed for HIV Ag/Ab com-
bination testing under a specific Current Procedural Termi-
nology code and the cost is covered without patient copay
by Affordable Care Act insurance plans and Medicaid
because HIV screening has a US Preventive Services Task
Force grade A recommendation.26 In addition, HIV Ag/Ab
combination testing can be performed in 30 minutes (if
results are negative) to 60 minutes (if results are reactive),
whereas the HIV RNA test requires 6 hours and the pooling
process can delay results by 4 to 7 days.
Although rapid HIV testing has certain advantages such
as the immediate provision of a result and the ability to test
in nonclinical outreach settings, our findings indicate that
the lower sensitivity for acute HIV infection is a major
limitation.23,27 The sensitivity of rapid, point-of-care HIV
testing for acute HIV infection may improve with the intro-
duction of rapid tests that can detect both HIV antigen and
antibody28 (approved by the FDA in 2014) or point-of-care
HIV-1 RNA tests29 (in development), although field testing
of point-of-care HIV antigen/antibody assays have hitherto
not had sufficient sensitivity for acute HIV infection.30
To address the low yield of currently available rapid HIV
antibody tests for acute HIV infection, 3 testing strategies
could increase the likelihood that high-risk individuals such
as MSM are accurately diagnosed. In the first strategy,
laboratory-based Ag/Ab combination testing would replace
the rapid HIV test as the initial screening test. This strategy
is consistent with the CDC/APHL HIV diagnostic testing
algorithm, sensitive for acute HIV infection, and cost-
effective, but patients would not receive an immediate
result. This strategy could be particularly useful for MSM
who (1) are testing on a regular basis, (2) are aware of the
advantages of Ag/Ab combination testing and willing to be
tested using phlebotomy, and (3) have reliable contact infor-
mation to receive their results.
In a second strategy, the rapidHIV testwould continue to
be the initial screening test, and if preliminarily positive, con-
firmatory testing and linkage to care would be performed. If
the result were negative, MSM and others at substantial risk
ofHIVwouldbeoffered an additional laboratory-basedAg/Ab
combination test to diagnose acute HIV infection potentially
missed with rapid testing. Although this approach is pre-
dicted to be cost-effective,31 the positive predictive value of a
reactiveHIVAg/Abcombination test after anegative rapidHIV
test was only 59% in our study, highlighting the importance
of confirming the diagnosis with an individual HIV RNA test
and indicating that this approach would be unsuited to low–
HIV prevalence populations.
In a third strategy, a rapid HIV test would be the initial
screening test, and if negative, HIV RNA testing would be
offered to MSM and others at substantial risk. This strategy
is resource intensive but also the most sensitive for acute
Table 3. Characteristics and Risk Behavior Information ofMenWhoHave SexWithMen Stratified by
HIV Statusa
Variable
HIV Infection Status, No. (%)
Relative Risk of
Acute HIV Infection
(95% CI)b P Value
Acute
(n = 151
[0.34%])
Established
(n = 956
[2.13%])
Negative
(n = 43 848
[97.54%])
Site
New York 62 (0.35) 542 (3.03) 17 306 (96.63) 1 [Reference]
California 78 (0.31) 331 (1.31) 24 946 (98.39) 0.87 (0.63-1.22) .42
North Carolina 11 (0.65) 83 (4.91) 1596 (94.44) 1.92 (1.01-3.63) .046
Age, y
<25 32 (0.40) 230 (2.89) 7704 (96.71) 1.46 (0.84-2.55) .18
25-34 70 (0.34) 426 (2.09) 19 914 (97.57) 1.24 (0.75-2.03) .40
35-44 29 (0.31) 184 (1.96) 9180 (97.73) 1.11 (0.63-1.96) .72
≥45 20 (0.28) 115 (1.60) 7032 (98.12) 1 [Reference]
Missing 0 1 (0.10) 18 (0.04) NC NC
Race/ethnicity
Black/African American 28 (0.54) 262 (5.07) 4875 (94.39) 2.03 (1.31-3.15) .002
Hispanic/Latino 39 (0.43) 230 (2.56) 8700 (97.00) 1.59 (1.07-2.35) .02
White 66 (0.28) 328 (1.38) 23 379 (98.34) 1 [Reference]
Asian 11 (0.26) 60 (1.41) 4172 (98.33) 0.93 (0.49-1.77) .83
Other 2 (0.36) 12 (2.13) 549 (97.51) 1.29 (0.32-5.25) .72
Unknown 5 (0.22) 64 (2.85) 2173 (96.92) 0.82 (0.33-2.02) .66
Risk behaviorsc
Sex with a known
HIV-positive partner
36 (0.47) 199 (2.62) 7368 (96.91) 1.55 (1.07-2.25) .02
Injection drug use 8 (1.75) 29 (6.33) 421 (91.92) 5.68 (2.81-11.51) <.001
Exchange sex for
money or drugs
0 1 (2.94) 33 (97.06) NC NC
Sex while high on drugs
or intoxicated
20 (0.23) 138 (1.56) 8662 (98.21) 0.62 (0.39-0.99) .047
Abbreviation: NC, not calculated
(1 cell included a 0).
a Characteristics and risk behavior
information is self-reported at the
time of testing. The test result (and
information collected at that test
event) is the unit of analysis.
Participants can only be diagnosed
with HIV infection (either acute or
established) once in this study but
participants who have an HIV test
negative result can be tested again.
bRelative risk of acute HIV infection
compared participants with acute
HIV infection and participants with a
negative HIV test result only
(excluding established HIV infection
in the denominator) and was
calculated using a log-linked
binomial regressionmodel
(GENMOD Procedure).
c The reference group for each
self-reported risk behavior is all
participants who did not report (by
checking a box on the form) that
particular risk behavior.
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HIV infection, and accordingly the most useful in settings
with the highest rates of acute HIV infection. Of note, HIV
RNA testing alone is not recommended, because approxi-
mately 3% to 5% of people with HIV will have a negative
RNA test result due to undisclosed antiretroviral use or elite
control of their HIV infection.32 Each strategy has advan-
tages in different settings, but all allow for acute HIV infec-
tion diagnosis, which is an important advantage over rapid
HIV antibody testing alone.
This study has several limitations. First, HIV testing was
conducted in high-risk populations (sexually transmitted
infection clinics and testing venues that focus on HIV test-
ing in MSM) and a majority of acute infections were
detected in MSM. These results may not be generalizable to
low-risk and non-MSM populations such as women. Never-
theless, MSM remain disproportionately affected by HIV,18
and implementation of effective strategies to diagnose
acute HIV infection in MSM and other at-risk populations is
needed. Second, preexposure prophylaxis and postexpo-
sure prophylaxis were not widely used at the time of this
study. Although there have not been false-negative results
with assays that detect HIV antibody or HIV RNA in persons
who become HIV infected while taking preexposure prophy-
laxis in clinical trials,33 HIV detection assays should be fur-
ther evaluated in this context as antiretroviral medications
can suppress HIV RNA and delay seroconversion when
given during acute infection.34
Conclusions
In a high-prevalence population, HIV screening using an HIV
Ag/Ab combination assay following a negative rapid test de-
tected 82% of acute HIV infections detectable by pooled HIV
RNA testing, with a positive predictive value of 59%. Further
research is needed to evaluate this strategy in lower-
prevalencepopulationsand inpersonsusingpreexposurepro-
phylaxis for HIV prevention.
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